FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Stanley Rhonda L.		 2. Issuer Name and Ticker or Trading Symbol

Adhera Therapeutics, Inc. [ ATRX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP Finance & Accounting
(Last)          (First)          (Middle)

C/O ADHERA THERAPEUTICS, INC., 4721 EMPEROR BLVD., SUITE 350		 3. Date of Earliest Transaction (MM/DD/YYYY)

11/1/2019
(Street)

DURHAM, NC 27703
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options to purchase common stock  $0.09  11/1/2019    A     350000       (1) 11/1/2029  common stock  350000  $0  350000  D   

Explanation of Responses:
(1)  Options to purchase 75,000 shares are exercisable immediately, options to purchase 75,000 shares shall vest on each of November 1, 2020, November 1, 2021 and November 1, 2022, options to purchase 25,000 shares shall vest on such date (if any) that the Issuer determines that the "Revenue Target" (as defined in the Employment Agreement dated October 29, 2019 between the Issuer and the reporting person (the "Employment Agreement")) is achieved, and options to purchase 25,000 shares shall vest on such date (if any) that the Issuer determines that the "Stock Price Target" (as defined in the Employment Agreement) has been achieved.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Stanley Rhonda L.
C/O ADHERA THERAPEUTICS, INC.
4721 EMPEROR BLVD., SUITE 350
DURHAM, NC 27703

SVP Finance & Accounting

Signatures
/s/ Rhonda Stanley 11/5/2019
**Signature of Reporting Person Date


Adhera Therapeutics (CE) (USOTC:ATRX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Adhera Therapeutics (CE).
Adhera Therapeutics (CE) (USOTC:ATRX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Adhera Therapeutics (CE).

Noticias sobre Adhera Therapeutics, Inc. ATRX

Real-Time news about Adhera Therapeutics Inc (CE) (OTCMarkets): 0 recent articles

Más de Adhera Therapeutics, Inc. Artículos de Noticias

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.